High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults

Annals of Oncology

Volumn 17, Issue 10, 2006, Pages 1479-1488

  Pedrazzoli, Paolo ^a   Ledermann, J A ^b   Lotz, J P ^c   Leyvraz, S ^d   Aglietta, M ^e   Rosti, G ^f   Champion, K M ^g   Secondino, S ^a   Selle, F ^c   Ketterer, N ^d   Grignani, G ^e   Siena, S ^a   Demirer, T ^h  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HÔPITAL TENON   (France)

^d Ctr Pluridisciplinaire d'Oncologie   (Switzerland)

^e UNIVERSITY OF TURIN   (Italy)

^f SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^g UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^h ANKARA UNIVERSITY   (Turkey)

Author keywords

High dose chemotherpy; Solid tumors; Stem cell transplantation

Indexed keywords

BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; METHOTREXATE; PACLITAXEL; THIOTEPA;

ADULT; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL STUDY; CLINICAL TRIAL; DATA ANALYSIS; DRUG FATALITY; DRUG MEGADOSE; EWING SARCOMA; GERM CELL TUMOR; HUMAN; LABORATORY; LUNG SMALL CELL CANCER; MEDICAL SPECIALIST; META ANALYSIS; OSTEOSARCOMA; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; SALVAGE THERAPY; SARCOMA; SOLID TUMOR; SYSTEMATIC REVIEW; TESTIS CANCER; UNSPECIFIED SIDE EFFECT;

EID: 33749611354     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl044     Document Type: Review

References (96)

1. Frei E 3rd, Canellos GP. Dose: A critical factor in cancer chemotherapy. Am J Med 1980; 69: 585-594.
2. Siena S, Bregni M, Brando B et al. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 74: 1905-1914.
3. Schmitz N, Linch DC, Dreger P et al. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
4. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360-1377.
5. Nitz UA, Mohrmann S, Fisher J et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: Results of a multicentre phase III trial. Lancet 2005; 366: 1935-1944.
6. Gratwohl A, Baldomero H, Demirer T et al. Hematopoetic stem cell transplantation for solid tumors in Europe. Ann Oncol 2004; 15: 653-660.
7. Woll, PJ, Hodgetts J, Lomax L et al. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 1995; 13: 652-659.
8. Steward WP, von Pawel J, Gatzemeier U et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: A prospective randomized study of 300 patients. J Clin Oncol 1998; 16: 642-650.
9. Thatcher N, Girling DJ, Hopwood P et al. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: Results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 2000; 18: 395-404.
10. Elias A, Cohen MH. Dose-intensive therapy in lung cancer. In High-dose cancer therapy pharmacology, hematopoietins, stem cells. JO Armitage and KH Antman (eds). Baltimore, Williams and Wilkins: 1995. pp. 824-846.
11. Banham S, Soukop M, Burnett A et al. Treatment of small cell carcinoma of lung with late dosage intensification programmes containing cyclophosphamide and mesna. Cancer Treat Rev 1983; 10 Suppl A: 73-77.
12. Smith IE, Evans BD, Harland SJ et al. High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma. Cancer Chemother Pharmacol 1985; 14: 120-124.
13. Cunningham D, Banham SW, Hutcheon AH et al. High-dose cyclophosphamide and VP 16 as late dosage intensification therapy for small cell carcinoma of lung. Cancer Chemother Pharmacol 1985; 15: 303-306.
14. Spitzer G, Farha P, Valdivieso M et al. High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma. J Clin Oncol 1986; 4: 4-13.
15. Humblet Y, Symann M, Bosly A et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: A randomized study. J Clin Oncol 1987; 5: 1864-1873.
16. Souhami RL, Hajichristou HT, Miles DW et al. Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer. Cancer Chemother Pharmacol 1989; 24: 321-325.
17. Pettengell R, Woll PJ, Thatcher N et al. Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 1995; 13: 148-156.
18. Elias AJ, Ibrahim J, Skarin AT et al. Dose-intensive therapy for limited-stage small-cell lung cancer: Long-term outcome. J Clin Oncol 1999; 17: 1175.
19. Fetscher S, Brugger W, Engelhardt R et al. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: A mature follow-up report. Ann Oncol 1999; 10: 561-567.
20. Kiura K, Ueoka H, Tabata M et al. Phase II study of high-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood stem cell transplantation for small-cell lung cancer. Proc Am Soc Clin Oncol 2003; 22: 632 (Abstr 2540).
21. Humblet Y, Bosquee L, Weynants P, Symann M. High-dose chemo-radiotherapy cycles for LD small cell lung cancer patients using G-CSF and blood stem cells. Bone Marrow Transplant 1996; 18 Suppl 1: S36-39.
22. Woll PJ, Thatcher N, Lomax L et al. Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: A randomized phase II trial in small-cell lung cancer patients. J Clin Oncol 2001; 19: 712-719.
23. Lorigan P, Woll PJ, O'Brien M et al. Randomized Phase III Trial of Dose-Dense Chemotherapy Supported by Whole-Blood Hematopoietic Progenitors in Better-Prognosis Small-Cell Lung Cancer. J Natl Cancer Inst 2005; 97: 666-674.
24. Buchholz E, Drings P, Pilz L et al. Final results from a single center, controlled study of standard versus dose intensified chemotherapy with sequential reinfusion of haematopoetic progenitor cells in small cell lung cancer. Proc Am Soc Clin Oncol 2003; 640 22: (Abstr 2572).
25. Leyvraz S, Ketterer N, Perey L et al. Intensification of chemotherapy for the treatment of solid tumours: Feasibility of a 3-fold increase in dose intensity with peripheral blood progenitor cells and granulocyte colony-stimulating factor. Br J Cancer 1995; 72: 178-182.
26. Leyvraz S, Perey L, Rosti G et al. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation. J Clin Oncol 1999; 17: 3531-3539.
27. Perey L, Benhattar J, Peters R et al. High tumour contamination of leukaphereses in patients with small cell carcinoma of the lung: A comparison of immunocytochemistry and RT-PCR. Br J Cancer 2001; 85: 1713-1721.
28. Bray F, Sankila, R, Ferlay, J et al. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38: 99-166.
29. Levin L, Simon R, Hrniuk W. Importance of multiagent chemotherapy regimens in ovarian carcinoma: Dose intensity analysis. J Natl Cancer Inst 1993; 85: 1732-1742.
30. McGuire W. How many more nails to seal the coffin of dose intensity? Ann Oncol 1997; 8: 311-313.
31. Shpall EJ, Stemmer SM, Bearman SI et al. High-dose chemotherapy with autologous bone marrow support for the treatment of epithelial ovarian cancer in cancer of the ovary. In: Markman M and Hoskins WJ (eds) Raven Press 1993. Chapter 24: Pp. 327-338.
32. Stiff PJ, Bayer R, Kerger C et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: A multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997; 15: 1309-1317.
33. Legros M, Daplat J, Fleury J et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. J Clin Oncol 1997; 15: 1302-1308.
34. Ledermann JA, Herd R, Maraninchi D et al. High-dose chemotherapy for ovarian carcinoma: Long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2001; 12: 693-699.
35. Cure H, Battista C, Gustalla JP et al. Phase III randomised trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/ SFGM-TC study. Proc Am Soc Clin Oncol 2004; 23: P.449 (Abstr 5006).
36. Ledermann JA, Frickhofen N, Wandt H et al. on behalf of the EBMT and AGO/ AI; A phase III randomised trial of sequential high dose chemotherapy (HDC) with peripheral blood stem cell support or standard dose Chemotherapy (SDC) for first-line treatment of ovarian cancer Proc Am Soc Clin Oncol 2005; 23: 449s (Abstr 5006).
37. Mulder POM, Willemse PHB, Aalders JG et al. High-dose Chemotherapy with Autologous Bone Marrow Transplantation in Patients with Refractory Ovarian Cancer. Eur J Cancer Clin Oncol 1989; 25: 645-649.
38. Viens P, Maraninchi D, Legros M et al. High Dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: A retrospective analysis of 35 patients treated in France. Bone Marrow Transplant 1990; 5: 227-233.
39. Benedetti-Panici P, Greggi S, Scambia G et al. High-dose Chemotherapy with Autologous Peripheral Stem Cell Support in Advanced Ovarian Cancer. Ann Med 1995; 27: 133-138.
40. Postmus PE, De Vries EG, De Vries-Hospars HG et al. Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation: A dose escalation study. Eur J Cancer Clin Oncol 1984; 20: 777-782.
41. Nichols CR, Williams SD, Loehrer PJ et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A South-Eastern Cancer Study Group and Southwest Oncology Group Protocol. J Clin Oncol 1991; 9: 1163-1172.
42. Motzer RJ, Mazumdar M, Gulati SC et al. Phase II trial of high dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1993; 85: 1828-1835.
43. Lotz JP, André T, Donsimoni R et al. High dose chemotherapy with ifosfamide, carboplatin and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adult. Cancer 1995; 75: 874-885.
44. Bhatia S, Abonour R, Porcu P et al. High dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 2000; 18: 3346-3351.
45. Brown ER, Nichols CR, Kneebone P et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 1992; 117: 124-128.
46. Beyer J. Kramar A, Mandanas R et al. High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables. J Clin Oncol 1996; 14: 2638-2645.
47. Kondagunta GV, Bacik J, Bajorin DF et al. Sequential dose-intensive Paclitaxel plus ifosfamide and carboplatin plus e' toposide with autologous stem cell transplantation for germ cell tumor (GCT) patients (pts). Proc Am Soc Clin Ooncol 2005; 23 (16s): 378s (Abstr 4503).
48. Horwich A. Salvage therapy of germ cell tumors. Br J Cancer 1995; 71: 901-903.
49. Lecesne A, Droz JP, Azab M et al. Phase II trial with single agent epirubicin as salvage chemotherapy in refractory germ cell tumors. Proc Am Soc Clin Oncol 1990; 9: 145 (Abstr 563).
50. Bokemeyer C, Beyer J, Metzner B et al. Phase II study of paclitaxel in patients with relapsed or cisplatin refractory testicular cancer. Ann Oncol 1996; 7: 31-34.
51. Pedrazzoli P, Perotti C, Da Prada GA et al. Collection of Circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer. Brit J Cancer 1997; 75: 1368-1372.
52. Rodenhuis S, Westermann A, Holtkamps MJ et al. Feasibility of multiple courses of high dose cyclophosphamide, thiotepa and carboplatin for breast cancer or germ cell cancer. J Clin Oncol 1996; 14: 1473-1483.
53. Lotz JP, Bui B, Théodore C et al. Refractory germ cell tumors (GCTs): salvage high-dose chemotherapy (HD-CT) combining 2 mobilization regimens followed by 3 HD-CT with peripheral blood stem cell transplantation (PBSCT): The TAXIF regime (GETUG). Ann Oncol 2005; 16: 411-418.
54. Vaena DA, Abonour R, Einhorn LH: Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol 2003; 21: 4100-4104.
55. Motzer RJ, Mazumdar M, Sheinfeld J et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000; 18: 1173-1180.
56. Rick O, Bokemeyer C, Beyer J et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 2001; 19: 81-88.
57. Shamash J, O'Doberty CA, Oliver RT et al. Should high dose chemotherapy be used to consolidate second or third line treatment in refractory germ cell tumours? Acta Oncol 2000; 39: 857-863.
58. Fields KF, Perkins JB, Partyka JS et al. High-dose thiotepa, novantrone, and taxol (TNT) followed by autologous stem cell transplant; results of a phase II study in women with chemoresponsive metastatic breast cancer. Proc Am Soc Clin Oncol 1999; 18: 49a (Abstr 182).
59. Pico JL, Rosti G, Kamar A et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 2005; 16: 1152-1159.
60. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603.
61. Schmoll HJ, Kollmannsberger C, Metzner B et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: An extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 2003; 21: 4083-4091.
62. Bokemeyer C, Schleucher N, Metzner B et al. First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: A prospective trial. Br J Cancer 2003; 89: 29-35.
63. Rosti G, De Giorgi U, Wandt H et al. First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: The experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party. Bone Marrow Transplant 2004; 34: 1033-1037.
64. Droz JP, Kramar A, Pico JL. Prediction of long-term response after high-dose chemotherapy with autologous bone marrow transplantation in the salvage treatment of non-seminomatous germ cell tumours. Eur J Cancer 1993; 29A: 818-821.
65. Motzer R, Sheinfeld J, Mazumdar M et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000; 18: 2413-2418.
66. Hartmann JT, Schleuler N, Metzner B et al. Sequential HD VIP-chemotherapy with autologous PBSC-Transplantation as first-line treatment in patients with primary mediastinal non-seminomatous germ cell cancer. Proc Am Soc Clin Oncol 2002; 21: 186a (Abstr 741).
67. Schmoll HJ, Souchon R, Krege S et al. European consensus on diagnosis and treatment of germ cell cancer: A report of the European germ cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15: 1377-1399.
68. Clark MA, Fisher C, Judson I, Thomas JM. Soft tissue sarcomas in adults. N Engl J Med 2005; 18: 701-711.
69. Van Glabbeke M, van Oosterom AT, Oosterhuis JW et al. Prognostic factors in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens. A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999; 17: 50-57.
70. Reichardt P, Tilgner J, Hohenberger P et al. Dose-intensive chemotherapy with ifosfamide, epirubicin and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: A phase II study. J Clin Oncol 1998; 16: 1438-1443.
71. Leyvraz S, Bacchi M, Cerny T et al. Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas: Swiss Group for Clinical Research. Ann Oncol 1998; 9: 877-884.
72. Reichardt P. High-dose chemotherapy in adult soft tissue sarcoma. Crit Rev Oncology/Hematology 2000; 41: 157-167.
73. Blay J, van Glabbeke M, Nielsen OS et al. Five-years survivors in patients with advanced soft tissue sarcoma treated with doxorubicin: A study on 1742 patients. Proc Am Soc Clin Oncol 1998; 17: 512a.
74. Elias AD, Ayash LJ, Wheeler C et al. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant 2005; 15: 373-379.
75. Blay J, Bouhour D, Ray-Coquard I, Dumonet C, Philip T, Biron P et al. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol 2000; 18: 3643-3650.
76. Kessinger A, Petersen K, Bishop M, Schmit-Pokorny K: High dose therapy with autologous hematopoietic stem cell rescue for patients with metastatic soft tissue sarcoma. Proc Am Soc Clin Oncol 1994; 13: 480a.
77. Reichardt P, Tilgner J, Mapara MY et al. Dose intensive chemotherapy with stem cell support for adult patients with advanced soft tissue sarcoma: A phase I study. Sarcoma 1997; 1: 219a.
78. Dumontet C, Biron P, Bouffet E et al. High dose chemotherapy with ABMT in soft tissue sarcomas: A report of 22 cases. Bone Marrow Transplant 1992; 10: 405-408.
79. Montemurro F, Grosso F, Ferrante P et al. High-dose chemotherapy with hematopoietic stem cell transplant (HDCT/HSCT) for soft tissue sarcoma (STS) of the adult: Analysis of the European Group for Blood and Marrow Transplantation (EBMT) Registry. Proc Am Soc Clin Oncol 2001; 20: 363a.
80. Kozuka T, Kiura K, Katayama H et al. Tandem high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation for recurrent soft tissue sarcoma. Anticancer Res 2002; 22: 2939-2944.
81. Schlemmer M, Wendtner CM, Falk M et al. Efficacy of consolidation high-dose chemotherapy (HDCT) with ifosfamide carboplatin and etoposide followed by peripheral blood stem cell rescue (PBSCR) in chemosensitive patients with metastatic soft tissue sarcomas. Proc Am Soc Clin Oncol 2004; 23: 817 (Abstr 9014).
82. Mesia R, Sola C, Lopez Pousa A et al. High-dose chemotherapy and autologous bone marrow transplantation in high-grade metastatic sarcomas. Rev Clin Esp 1994; 194: 960-965.
83. Kasper B, Lehnert T, Bernd L et al. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant 2004; 34: 37-41.
84. Carli M, Colombatti R, Oberlin O et al. European Intergroup Studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcom: Final results and analysis of prognostic factors. J Clin Oncol 2004; 22: 4787-4794.
85. Fagioli F, Aglietta M, Tienghi A et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: An Italian sarcoma group study. J Clin Oncol 2002; 20: 2150-2156.
86. Meyers PA, Krailo MD, Ladanyi M et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 2001; 19: 2812-2820.
87. Burdach S, Meyer-Bahlburg A, Laws R et al. High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol 2003; 21: 3072-3078.
88. Multivariate Analysis on EBMT Ewing Tumour Data in 2003. Coordinator Prof. R. Ladenstein. In: EBMT Report 2003, Paediatric Diseases Working Party Solid Tumours, p. 62.
89. Strauss SJ, McTiernan A, Driver D et al. Single Center Experience of a New Intensive Induction Therapy for Ewing's Family of Tumors: Feasibility, Toxicity, and Stem Cell Mobilization Properties. J Clin Oncol 2003; 21: 2974-2981.
90. Tienghi A, Ferrari S, Mercuri M et al. High dose chemotherapy with peripheral blood stem cell (P.B.S.C.) rescue in metastatic Ewing's sarcoma at diagnosis. Proc Am Soc Clin Oncol 2005; 23 (16s): 817 (Abstr 9004).
91. Oberlin O, Habrand JL. Ewing's sarcoma: Towards a common protocol for adults and children. Cancer Radiother 2000; 4 Suppl 1: 141s-144s.
92. Hortobagyi G. High dose chemotherapy in the era of targeted therapies. J Clin Oncol 2004; 22: 2263-2266.
93. Rodenhuis S, Bontenbal M, Beex L et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003; 349: 7-16.
94. Crown J. Smart bombs versus blunderbusses: High-dose chemotherapy for breast cancer. Lancet 2004; 364: 1299-1300.
95. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
96. Lake RA, Robinson BWS. Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 2005; 5: 397-405.